Stay updated on Subcutaneous vs Intravenous Atezolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Subcutaneous vs Intravenous Atezolizumab in NSCLC Clinical Trial page.

Latest updates to the Subcutaneous vs Intravenous Atezolizumab in NSCLC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check19 days agoChange Detected- Added a new revision note 'Revision: v3.3.3' and removed 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2' from the page footer. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check26 days agoChange DetectedNew sections Adverse Events, Outcome Measures, Participant Flow, Contacts/Locations, and Study Status were added in versions dated 2025-11-23 and 2025-12-11; a prior entry dated 2024-11-21 was removed.SummaryDifference0.7%

- Check47 days agoChange DetectedRevision from v3.2.0 to v3.3.2 is shown in the Record History, reflecting a system/UI update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check54 days agoChange DetectedNotice about government funding and operating status at the top of the page was removed; this appears to be a site-wide administrative update rather than a modification to the study record or its results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check69 days agoChange DetectedThe new screenshot shows the same study record history and page sections as the old version, with only minor visual adjustments; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check97 days agoChange DetectedAdded a prominent operating-status notice and a v3.2.0 version tag, replacing the prior v3.1.0 revision.SummaryDifference10%

Stay in the know with updates to Subcutaneous vs Intravenous Atezolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Subcutaneous vs Intravenous Atezolizumab in NSCLC Clinical Trial page.